JNJ7777120, > = 98%( HPLC)

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

JNJ7777120 has been used as a histamine-4 receptor antagonist:to study its effects on the pro-inflammatory microglia in ratsto study its effects on the Parkinson′s-like pathology in rat brainto study its effects on the histamine receptor interaction in periodontal ligament fibroblasts (PDLF)

Biochem/physiol Actions

JNJ7777120 is a potent, selective non-imidazole H₄ histamine receptor antagonist.

JNJ7777120 may exhibit neuroprotective effects against ischemic brain damage. It acts as an anti-inflammatory agent to treat inflammatory diseases. JNJ7777120 is observed to reduce colonic injury, cytokine production, and neutrophil infiltration.

Features and Benefits

This compound is featured on the Histamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

5, 25 mg in glass bottle